MTC NL5
Alternative Names: MTC-NL5Latest Information Update: 03 Nov 2022
At a glance
- Originator Biotts
- Class Nonsteroidal anti-inflammatories
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Research Unspecified
Most Recent Events
- 21 Sep 2022 MTC NL5 is available for licensing as of 21 Sep 2022. https://biotts.com/en/our-products/ 3707319
- 21 Sep 2022 Early research in undefined indication in Poland (Transdermal), as of September 2022 (Biotts pipeline, September 2022)
- 21 Sep 2022 Biotts plans for a phase I study of MTC NL5 (Transdermal) (Biotts pipeline, September 2022)